MedTrace Logo

Analysis of Pharmacodynamic Changes With AUY922A, an HSP90 Inhibitor

NCT01024283 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2009-12-02

No results posted yet for this study

Summary

The principal research objective of this additional research protocol is to support the collection, storage and use of tumour and surrogate (peripheral blood mononuclear cells - PBMNCs). The objective of this study is to perform assays to study pharmacodynamic (PD) markers that confirm target modulation.

Conditions

  • Advanced Solid Malignancies

Sponsors & Collaborators

  • Institute of Cancer Research, United Kingdom

    collaborator OTHER

  • Royal Marsden NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Dr Udai Banerji · Institute of Cancer Research, United Kingdom

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2013-08-31
Completion
2013-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01024283 on ClinicalTrials.gov